trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['pancreatic', 't-dxd']
for the most part, her-2 status and t-dxd does not appear to make much of a difference in #pancreaticcancer. but quite effective in appropriately selected bile duct cancers. #asco23 so much of pancreato-biliary is really pancreatic versus biliary. 
Pancreatic cancer researcher and GI pathologist. Striving to improve the lives of patients with cancer. Tweets are from Earth unless otherwise specified.